News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
BioOutsource says it has quadrupled its revenue from biologics testing and biosimilar characterisation in the last 18 months and is opening a new facility to cope with continued demand.
Commercial-scale hES culturing is now a possibility thanks to a new technique that - the developers claim - resolves the ethical, technical and regulatory issues that have held back research.
special report
It is no clearer how the US will govern biosimilar naming, approval and substitution despite a day-long Federal Trade Commission (FTC) workshop that produced heated debate but few concrete answers.